Sustained intrauterine release of levonorgestrel over five years
- PMID: 3086130
- DOI: 10.1016/s0015-0282(16)49397-0
Sustained intrauterine release of levonorgestrel over five years
Abstract
Two models of levonorgestrel-releasing intrauterine devices were studied. Model A was designed to deliver 20 micrograms/day, and model B was designed to deliver 30 micrograms/day. Plasma concentrations of levonorgestrel were determined in blood samples taken from women who used the levonorgestrel-releasing intrauterine devices (IUDs) and who participated in a clinical trial for more than 5 years. During clinical studies IUDs have been removed for various reasons between 8 and 40 months after insertion. The rate of release of levonorgestrel from the IUDs was calculated by determining the remaining amount of levonorgestrel. Plasma concentrations of levonorgestrel ranged between a mean +/- standard deviation (SD) concentration of 166 +/- 75 pg/ml and 131 +/- 32 pg/ml for the first 18 months of use and between 101 +/- 37 pg/ml and 74 +/- 15 pg/ml at 24 and 60 months after insertion of the IUD. The plasma concentrations from 24 months through 60 months were significantly lower than concentrations measured during initial months of IUD use, but not between the two devices. There was a strong correlation between the time of use and the amount of levonorgestrel lost from the IUDs. The calculated mean daily release of levonorgestrel was 17.6 micrograms for model A and 22.2 micrograms for model B. This gives a calculated lifetime of more than 6 years for a levonorgestrel-releasing IUD.
PIP: 2 models of levonorgestrel-releasing IUDs were studied. Model A was designed to deliver 20 mcg/day and model B 30 mcg/day. Plasma concentrations of levonorgestrel were determined in blood samples taken from who had used the levonorgestrel-releasing IUDs and who had participated in a clinical trial for more than 5 years. During clinical studies, IUDs have been removed for various reasons between 8-40 months after insertion. The rate of release of levonorgestrel from the IUDs was calculated by determining the remaining amount of levonorgestrel. Plasma concentrations of levonorgestrel ranged between a mean +or- standard deviation concentration of 166 +or- 75 pg/ml and 131 +or- 32 pg/ml for the 1st 18 months of use and between 101 +or- 37 pg/ml and 74 +or- 15 pg/ml at 24 and 60 months after IUD insertion. Plasma concentrations from 24 to 60 months were significantly lower than concentrations measured during the initial months of IUD use, but not between the 2 devices. There was a strong correlation between the time of use and the amount of levonorgestrel lost from the IUDs. The calculated mean daily release of levonorgestrel was 17.6 mcg for model A and 22.2 mcg for model B. This gives a calculated lifetime of more than 6 years for a levonorgestrel-releasing IUD.
Similar articles
-
Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.Contraception. 1980 Mar;21(3):225-33. doi: 10.1016/0010-7824(80)90003-7. Contraception. 1980. PMID: 6771090
-
Five years' experience with levonorgestrel-releasing IUDs.Contraception. 1986 Feb;33(2):139-48. doi: 10.1016/0010-7824(86)90080-6. Contraception. 1986. PMID: 3084167 Clinical Trial.
-
Acceptability of an experimental intracervical device: results of a study controlling for selection bias.Contraception. 1989 Jan;39(1):73-84. doi: 10.1016/0010-7824(89)90016-4. Contraception. 1989. PMID: 2491982 Clinical Trial.
-
An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.Contraception. 1991 Dec;44(6):573-88. doi: 10.1016/0010-7824(91)90078-t. Contraception. 1991. PMID: 1773615 Review.
-
Endometrial morphological changes in IUD users: a review.Contraception. 1987 Jul;36(1):1-10. doi: 10.1016/0010-7824(87)90057-6. Contraception. 1987. PMID: 3117492 Review.
Cited by
-
Impact of prior levonorgestrel intrauterine device use at the time of embryo transfer.Reprod Fertil. 2024 Dec 20;5(4):e240099. doi: 10.1530/RAF-24-0099. Print 2024 Oct 1. Reprod Fertil. 2024. PMID: 39541166 Free PMC article.
-
Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.Int J Womens Health. 2010 Aug 9;1:45-58. doi: 10.2147/ijwh.s4350. Int J Womens Health. 2010. PMID: 21072274 Free PMC article.
-
Role of the levonorgestrel intrauterine system in effective contraception.Patient Prefer Adherence. 2013 Aug 9;7:777-85. doi: 10.2147/PPA.S36948. eCollection 2013. Patient Prefer Adherence. 2013. PMID: 23990713 Free PMC article.
-
Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.Drug Saf. 2004;27(15):1185-204. doi: 10.2165/00002018-200427150-00003. Drug Saf. 2004. PMID: 15588115
-
A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.Drug Saf. 1996 Dec;15(6):430-40. doi: 10.2165/00002018-199615060-00006. Drug Saf. 1996. PMID: 8968696 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources